SCHEMBL5860075

SCHEMBL5860075

CCOC(=O)c1c(Cl)nc2ccc(OC)cc2c1CCl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.49
KDM4E B2RXH2 9/20 0.49
HPGD P15428 7/20 0.49
CTSL P07711 1/20 0.47
CTSB P07858 1/20 0.47
GAA P10253 3/20 0.47
HSD17B10 Q99714 2/20 0.47
PLA2G2A P14555 1/20 0.46
MAPT P10636 4/20 0.46
ATM Q13315 1/20 0.46
POLB P06746 2/20 0.45
LMNA P02545 2/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
PRNP P04156 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28601043 0.87 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDCTSLCTSB
SCHEMBL29799182 0.87 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDCTSLCTSB
SCHEMBL7092995 0.87 DHODH (0.52) ALDH1A1KDM4EHPGDHSD17B10PLA2G2A
SCHEMBL5859919 0.85 TSHR (0.48) ALDH1A1KDM4EHPGDGAAPLA2G2A
SCHEMBL5860044 0.82 KDM4E (0.62) ALDH1A1KDM4EHPGDGAAHSD17B10
SCHEMBL5860177 0.81 MAPT (0.44) ALDH1A1KDM4EHPGDGAAMAPT
SCHEMBL5859933 0.81 KDM4E (0.43) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL5860955 0.80 ALDH1A1 (0.42) ALDH1A1KDM4EHPGDGAAMAPT
SCHEMBL30572414 0.80 ALDH1A1 (0.58) ALDH1A1KDM4EHPGDCTSLCTSB
SCHEMBL5862670 0.80 TNF (0.39) ALDH1A1KDM4EHPGDGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135478-B2 Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2006-11-14 US disclosed
US-7053102-B2 Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2006-05-30 US disclosed
US-20050038064-A1 Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) 2005-02-17 US disclosed
US-20040254163-A1 New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) 2004-12-16 US disclosed
US-6815546-B2 ANTICANCER AGENTS SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-11-09 US disclosed
US-6797715-B1 Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-09-28 US disclosed
US-6762301-B2 Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them SOCIETE DE CONSEILS DE RECHERCHES ET APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-07-13 US disclosed
US-20030004150-A1 New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them IPSEN PHARMA S.A.S. (FR) 2003-01-02 US disclosed
US-20020160994-A1 New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) 2002-10-31 US disclosed
US-6339091-B1 USEFUL IN THERAPY OF OF VIRAL INFECTIONS, PARASITIC DISEASES AND CANCER SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254163-A1 New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them TOP2A, TOP1, MCL1 ALDH1A1 778/4885KDM4E 4381/4885HPGD 161/4885
US-20030004150-A1 New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them TOP1, TOP2A, TYMP ALDH1A1 795/4885KDM4E 4443/4885HPGD 426/4885
US-20050038064-A1 Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione MCL1, BRCA1, API5 ALDH1A1 284/4885KDM4E 699/4885HPGD 422/4885
US-20020160994-A1 New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them TOP2A, TOP1, TOP2B ALDH1A1 1530/4885KDM4E 4167/4885HPGD 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.